Remus PharmaceuticalsNSE:REMUS -1.02%55 ROA % is 6.80% as of Mar. 2026, which is 43% below its 10-year median of 11.85. GuruFocus rates NSE:REMUS with a GF Score™ of 55/100 and a GF Value™ of ₹2,071.36 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 120 Medical Distribution companies, Remus Pharmaceuticals ranks better than 84.17% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Remus Pharmaceuticals's annualizedNet Income for the quarter that ended in Mar. 2026 was ₹390 Mil.
Remus Pharmaceuticals's average Total Assets over the quarter that ended in Mar. 2026 was ₹5,734 Mil. Therefore, Remus Pharmaceuticals's annualized ROA % for the quarter that ended in Mar. 2026 was 6.80%.
The historical rank and industry rank for Remus Pharmaceuticals's ROA % or its related term are showing as below:
NSE:REMUS'
s ROA % Range Over the Past 10 Years
Min: 7.03 Med: 11.85 Max: 25.12
Current: 7.03
During the past 7 years, Remus Pharmaceuticals's highest ROA % was 25.12%. The lowest was 7.03%. And the median was 11.85%.
NSE:REMUS's ROA % is ranked better than 84.17% of 120
companies
in the Medical Distribution industry
Industry Median: 2.23
vs NSE:REMUS: 7.03
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is two times the semi-annual (Mar. 2026) net income data. The Revenue data used here is two times the semi-annual (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Remus Pharmaceuticals's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Remus Pharmaceuticals ROA % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Remus Pharmaceuticals's ROA % distribution charts can be found below:
* The bar in red indicates where Remus Pharmaceuticals's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Mar. 2026) net income data.
ROA % is displayed in the 30-year financial page.
Remus Pharmaceuticals (NSE:REMUS) has a ROA % of 6.80% as of Mar. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Remus Pharmaceuticals and its competitors. This is 43% below median its historical median of 11.85. Over the past decade, Remus Pharmaceuticals' ROA % has ranged from 7.03 to 25.12. According to the industry distribution chart, Remus Pharmaceuticals ranks #19 out of 120 companies in the Medical Distribution industry, placing it in the top 15.8%.
Is Remus Pharmaceuticals' ROA % too high?
Remus Pharmaceuticals' current ROA % of 6.80% is 43% below median its 10-year median of 11.85. Over the past 10 years, this metric has ranged from a low of 7.03 to a high of 25.12. The Medical Distribution industry median ROA % is 2.23. Remus Pharmaceuticals' value of 6.80% is 204.9% above this industry median. Based on the distribution chart, Remus Pharmaceuticals ranks #19 out of 120 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Remus Pharmaceuticals has a GF Score™ of 55/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Remus Pharmaceuticals' ROA % compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Remus Pharmaceuticals ranks #19 out of 120 companies for ROA %. This places Remus Pharmaceuticals in the top 16% of its industry — outperforming the majority of peers. The industry median ROA % is 2.23. Remus Pharmaceuticals' value of 6.80% is 204.9% above this benchmark. Historically, Remus Pharmaceuticals' own ROA % has ranged from 7.03 to 25.12 over the past decade. While the company's 10-year median is 11.85 vs. the industry median of 2.23, Remus Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Medical Distribution company?
The median ROA % among Medical Distribution companies is 2.23, based on 120 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Remus Pharmaceuticals's current ROA % of 6.80% is 204.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Remus Pharmaceuticals and its competitors. For the Medical Distribution industry, the median ROA % is 2.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Remus Pharmaceuticals's current ROA % is 6.80%, which is 43% below median its own 10-year median of 11.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Remus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Remus Pharmaceuticals (NSE:REMUS) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹2,071.36, compared to a current price of ₹793.70 — trading 61.7% below its estimated fair value. The current ROA % is 6.80%, which is 43% below median its 10-year median of 11.85 and 204.9% above the Medical Distribution industry median of 2.23. Remus Pharmaceuticals' overall GF Score™ is 55/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Remus Pharmaceuticals (NSE:REMUS), the current ROA % is 6.80% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Remus Pharmaceuticals (NSE:REMUS) Overvalued in 2026?
Based on GuruFocus' analysis, Remus Pharmaceuticals stock appears to be undervalued.
The current stock price of ₹793.70 is trading 61.7% below its estimated GF Value™ of ₹2,071.36.
GuruFocus considers Remus Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for NSE:REMUS:
ROA %: 6.80% (43% below median its 10-year median of 11.85)
GF Value™: ₹2,071.36 vs. price of ₹793.70 (61.7% below fair value)
Industry Position: 204.9% above the Medical Distribution median (#19 of 120)
No single metric tells the full story. See the NSE:REMUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Remus Pharmaceuticals Ltd is engaged in the marketing & distribution of finished formulations of pharmaceutical drugs. The company also deals in API (Active Pharmaceutical Ingredient). It also provides technical consultancy services to various distributors for the preparation of reports on the dossiers of the products to be registered by them in various countries. Remus Pharmaceuticals market niche medicinal combinations. It exports generic drugs by conducting intensive market research in the pharmaceutical industry to expand its product portfolio.
55GF Score
Get the complete analysis for NSE:REMUS
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:REMUS has been successfully added to your 
